MPO and coronary artery disorder: In the age category 65–75 years, the use of lipid-lowering drugs was more important (β -0.09 mAU/mL, 95% CI -0.17;-0.01) and in participants >75 years, HDL levels (β -0.12 mAU/mL, 95% CI -0.21;-0.04) and a history of CHD (β -0.12 mAU/mL, 95% CI -0.23;0.00) were only weak determinants of MPO-DNA complex levels.